GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (STU:PBN) » Definitions » Net Interest Income

Alterity Therapeutics (STU:PBN) Net Interest Income : €0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Alterity Therapeutics Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Alterity Therapeutics's net interest income for the three months ended in Jun. 2024 was €0.00 Mil. Its net interest income for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00 Mil.

Alterity Therapeutics Net Interest Income Historical Data

The historical data trend for Alterity Therapeutics's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alterity Therapeutics Net Interest Income Chart

Alterity Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 - 0.01 0.17

Alterity Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Alterity Therapeutics Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Net Interest Income Related Terms

Thank you for viewing the detailed overview of Alterity Therapeutics's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Alterity Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (STU:PBN) » Definitions » Net Interest Income
Comparable Companies
ASX:TRP ASX:IMC ASX:BIT ASX:ACR ASX:BTC ASX:1AD ASX:1AI ASX:ANR ASX:MEM ASX:NYR VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
ATHE:USA PBN0:Germany PBN:Germany ATH:Australia
Address
350 Collins Street, Level 14, Melbourne, VIC, AUS, 3000
Website
https://www.alteritytherapeutics.com
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.

Alterity Therapeutics Headlines

No Headlines